echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Johnson and Johnson's new crown vaccine announces the latest positive developments this month will begin phase 3 trials.

    Johnson and Johnson's new crown vaccine announces the latest positive developments this month will begin phase 3 trials.

    • Last Update: 2020-09-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Today, Johnson and Johnson announced that Ad26.COV2.S, a candidate new crown vaccine developed by the company, has achieved new positive results in preclinical studies.
    Data published today in Nature Medicine show that the new coronavirus serotype 26 (Ad26) vector, called Ad26.COV2.S, causes the production of mesothroid antibodies in Syrian golden hamsters and prevents serious clinical symptoms of neo-coronary pneumonia, including weight loss, pneumonia and death.
    July, Johnson and Johnson published the Ad26.COV2.S vaccine in the journal Nature, which triggers an immune response in preclinical studies of non-human primates (NHPs).
    Nature's study showed that Ad26.COV2.S needed only one inoculation, which not only stimulated a strong mesothetic antibody and cellular immune response in non-human primate models, but also achieved full or almost complete protection in subsequent drug tests on animals.
    a recently published study in Nature, Johnson and Johnson continued to test the vaccine candidate in golden hamsters, which are often more likely than NHP to show symptoms of severe new coronavirus infections.
    in this preclinical study, the researchers exempted gold hamsters from a single injection of the Ad26.COV2.S vaccine, which induced nalocation of antibodies in all vaccinated animals.
    four weeks later, the animals were exposed to high doses of SARS-CoV-2 virus.
    less weight and fewer viruses in their lungs and other organs than unvaccinated control animals, the study said.
    animals that have been vaccinated have not died.
    , the researchers found a negative correlation between the negative antibody response and weight loss and lung virus replication.
    plans to begin Phase 3 trials this month and will continue to work to expand vaccine manufacturing capacity to ensure global supply after proven vaccine effectiveness.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.